2022 ICD-10-CM Diagnosis Code D47.4

Osteomyelofibrosis

    2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code
  • D47.4 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2022 edition of ICD-10-CM D47.4 became effective on October 1, 2021.
  • This is the American ICD-10-CM version of D47.4 - other international versions of ICD-10 D47.4 may differ.
Applicable To
  • Chronic idiopathic myelofibrosis
  • Myelofibrosis (idiopathic) (with myeloid metaplasia)
  • Myelosclerosis (megakaryocytic) with myeloid metaplasia
  • Secondary myelofibrosis in myeloproliferative disease
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as D47.4. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • acute myelofibrosis (
    ICD-10-CM Diagnosis Code C94.4

    Acute panmyelosis with myelofibrosis

      2016 2017 2018 2019 2020 2021 2022 Non-Billable/Non-Specific Code
    Applicable To
    • Acute myelofibrosis
    Type 1 Excludes
    • myelofibrosis NOS (D75.81)
    • secondary myelofibrosis NOS (D75.81)
    C94.4-
    )
The following code(s) above D47.4 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to D47.4:
  • C00-D49
    2022 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • D37-D48
    2022 ICD-10-CM Range D37-D48

    Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes

    Note
    • Categories D37-D44, and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made.
    Type 1 Excludes
    • neoplasms of unspecified behavior (D49.-)
    Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes
Approximate Synonyms
  • Myelofibrosis with myeloid metaplasia
  • Myelosclerosis with myeloid metaplasia
Clinical Information
  • A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. The cause is unknown. The median survival time is 3-5 years from diagnosis. (who, 2001)
  • A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by cytokines arising from the abnormal clone.
  • A progressive, chronic disease in which the bone marrow is replaced by fibrous tissue and blood is made in organs such as the liver and the spleen, instead of in the bone marrow. This disease is marked by an enlarged spleen and progressive anemia.
ICD-10-CM D47.4 is grouped within Diagnostic Related Group(s) (MS-DRG v39.0):
  • 814 Reticuloendothelial and immunity disorders with mcc
  • 815 Reticuloendothelial and immunity disorders with cc
  • 816 Reticuloendothelial and immunity disorders without cc/mcc

Convert D47.4 to ICD-9-CM

Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
Code annotations containing back-references to D47.4:
  • Type 1 Excludes: D61.82
    , D75.81
    ICD-10-CM Diagnosis Code D61.82

    Myelophthisis

      2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code
    Applicable To
    • Leukoerythroblastic anemia
    • Myelophthisic anemia
    • Panmyelophthisis
    Code Also
    • the underlying disorder, such as:
    • malignant neoplasm of breast (C50.-)
    • tuberculosis (A15.-)
    Type 1 Excludes
    • idiopathic myelofibrosis (D47.1)
    • myelofibrosis NOS (D75.81)
    • myelofibrosis with myeloid metaplasia (D47.4)
    • primary myelofibrosis (D47.1)
    • secondary myelofibrosis (D75.81)
    ICD-10-CM Diagnosis Code D75.81

    Myelofibrosis

      2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code Manifestation Code
    Applicable To
    • Myelofibrosis NOS
    • Secondary myelofibrosis NOS
    Code First
    • the underlying disorder, such as:
    • malignant neoplasm of breast (C50.-)
    Type 1 Excludes
    • acute myelofibrosis (C94.4-)
    • idiopathic myelofibrosis (D47.1)
    • leukoerythroblastic anemia (D61.82)
    • myelofibrosis with myeloid metaplasia (D47.4)
    • myelophthisic anemia (D61.82)
    • myelophthisis (D61.82)
    • primary myelofibrosis (D47.1)
    Use Additional
    • code, if applicable, for associated therapy-related myelodysplastic syndrome (D46.-)

Diagnosis Index entries containing back-references to D47.4:
  • Myelofibrosis D75.81
    ICD-10-CM Diagnosis Code D75.81

    Myelofibrosis

      2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code Manifestation Code
    Applicable To
    • Myelofibrosis NOS
    • Secondary myelofibrosis NOS
    Code First
    • the underlying disorder, such as:
    • malignant neoplasm of breast (C50.-)
    Type 1 Excludes
    • acute myelofibrosis (C94.4-)
    • idiopathic myelofibrosis (D47.1)
    • leukoerythroblastic anemia (D61.82)
    • myelofibrosis with myeloid metaplasia (D47.4)
    • myelophthisic anemia (D61.82)
    • myelophthisis (D61.82)
    • primary myelofibrosis (D47.1)
    Use Additional
    • code, if applicable, for associated therapy-related myelodysplastic syndrome (D46.-)
    • secondary D75.81
      ICD-10-CM Diagnosis Code D75.81

      Myelofibrosis

        2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code Manifestation Code
      Applicable To
      • Myelofibrosis NOS
      • Secondary myelofibrosis NOS
      Code First
      • the underlying disorder, such as:
      • malignant neoplasm of breast (C50.-)
      Type 1 Excludes
      • acute myelofibrosis (C94.4-)
      • idiopathic myelofibrosis (D47.1)
      • leukoerythroblastic anemia (D61.82)
      • myelofibrosis with myeloid metaplasia (D47.4)
      • myelophthisic anemia (D61.82)
      • myelophthisis (D61.82)
      • primary myelofibrosis (D47.1)
      Use Additional
      • code, if applicable, for associated therapy-related myelodysplastic syndrome (D46.-)
      • in myeloproliferative disease D47.4
    • with myeloid metaplasia D47.4
    • idiopathic D47.4 (chronic)
  • Myelosclerosis D75.89
    ICD-10-CM Diagnosis Code D75.89

    Other specified diseases of blood and blood-forming organs

      2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code
    • megakaryocytic D47.4
      • with myeloid metaplasia D47.4
    • with myeloid metaplasia D47.4
  • Osteomyelofibrosis D47.4

ICD-10-CM Codes Adjacent To D47.4
D46.Z Other myelodysplastic syndromes
D46.9 Myelodysplastic syndrome, unspecified
D47 Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.0 Mast cell neoplasms of uncertain behavior
D47.01 Cutaneous mastocytosis
D47.02 Systemic mastocytosis
D47.09 Other mast cell neoplasms of uncertain behavior
D47.1 Chronic myeloproliferative disease
D47.2 Monoclonal gammopathy
D47.3 Essential (hemorrhagic) thrombocythemia
D47.4 Osteomyelofibrosis
D47.Z Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.Z1 Post-transplant lymphoproliferative disorder (PTLD)
D47.Z2 Castleman disease
D47.Z9 Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.9 Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified
D48 Neoplasm of uncertain behavior of other and unspecified sites
D48.0 Neoplasm of uncertain behavior of bone and articular cartilage
D48.1 Neoplasm of uncertain behavior of connective and other soft tissue
D48.2 Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system
D48.3 Neoplasm of uncertain behavior of retroperitoneum

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.